54.99
price down icon0.42%   -0.23
pre-market  Vorhandelsmarkt:  54.12   -0.87   -1.58%
loading
Schlusskurs vom Vortag:
$55.22
Offen:
$54.79
24-Stunden-Volumen:
679.43K
Relative Volume:
0.78
Marktkapitalisierung:
$3.41B
Einnahmen:
$45.48M
Nettoeinkommen (Verlust:
$169.95M
KGV:
20.99
EPS:
2.62
Netto-Cashflow:
$230.85M
1W Leistung:
-0.60%
1M Leistung:
+3.09%
6M Leistung:
+49.11%
1J Leistung:
+52.33%
1-Tages-Spanne:
Value
$54.28
$55.26
1-Wochen-Bereich:
Value
$54.28
$57.73
52-Wochen-Spanne:
Value
$32.50
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
Firmenname
Protagonist Therapeutics Inc
Name
Telefon
(510) 474-0170
Name
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
Mitarbeiter
124
Name
Twitter
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
PTGX's Discussions on Twitter

Vergleichen Sie PTGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
54.99 3.43B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-17 Eingeleitet Citigroup Buy
2024-12-06 Eingeleitet BMO Capital Markets Outperform
2024-12-06 Eingeleitet Goldman Neutral
2024-11-05 Eingeleitet Wedbush Outperform
2024-09-24 Eingeleitet TD Cowen Buy
2024-09-09 Eingeleitet Truist Buy
2023-10-30 Eingeleitet CapitalOne Overweight
2023-05-25 Fortgesetzt Jefferies Buy
2022-08-25 Eingeleitet JMP Securities Mkt Outperform
2022-02-11 Eingeleitet BTIG Research Buy
2021-10-12 Hochstufung JP Morgan Neutral → Overweight
2021-10-11 Hochstufung Northland Capital Market Perform → Outperform
2021-09-20 Herabstufung JP Morgan Overweight → Neutral
2021-05-24 Eingeleitet JMP Securities Mkt Outperform
2021-05-24 Eingeleitet Northland Capital Outperform
2021-01-06 Eingeleitet JP Morgan Overweight
2020-12-16 Eingeleitet Piper Sandler Overweight
2020-09-18 Bestätigt H.C. Wainwright Buy
2020-07-15 Eingeleitet Jefferies Buy
2020-05-18 Bestätigt H.C. Wainwright Buy
2019-07-08 Eingeleitet H.C. Wainwright Buy
2019-05-09 Hochstufung Stifel Hold → Buy
2018-12-06 Eingeleitet Nomura Buy
2018-01-29 Eingeleitet Stifel Buy
2017-07-21 Eingeleitet BTIG Research Buy
Alle ansehen

Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten

pulisher
Jul 22, 2025

Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Protagonist Therapeutics Inc. stock priceExplosive wealth accumulation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Protagonist Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal

Jul 22, 2025
pulisher
Jul 21, 2025

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lancaster Eagle-Gazette

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

Jul 21, 2025
pulisher
Jul 17, 2025

How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 15, 2025

How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛

Jul 12, 2025
pulisher
Jul 02, 2025

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech

Jul 02, 2025
pulisher
Jul 01, 2025

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com

Jul 01, 2025
pulisher
Jun 30, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman

Jun 30, 2025
pulisher
Jun 26, 2025

Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus

Jun 26, 2025
pulisher
Jun 24, 2025

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance

Jun 24, 2025
pulisher
Jun 20, 2025

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance

Jun 20, 2025
pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citi initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 16, 2025

How To Trade (PTGX) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada

Jun 14, 2025

Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
MOLINA ARTURO MD
Chief Medical Officer
Jun 09 '25
Option Exercise
8.04
10,000
80,400
93,892
MOLINA ARTURO MD
Chief Medical Officer
Jun 10 '25
Option Exercise
8.04
10,000
80,400
93,892
MOLINA ARTURO MD
Chief Medical Officer
Jun 10 '25
Sale
57.03
10,000
570,300
83,892
MOLINA ARTURO MD
Chief Medical Officer
Jun 09 '25
Sale
55.51
10,000
555,100
83,892
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):